Akorn guidance 'not a cause for alarm,' says Piper Jaffray Piper Jaffray believes Akorn's 2014 guidance is "not a cause for alarm" given the depth of the company's pipeline. Piper says Akorn's long-term growth story remains intact and it keeps an Overweight rating on the stock despite lowering its price target for shares to $28 from $29.
Akorn initiated with Outperform, $50 target at William Blair William Blair started shares of Akorn with an Outperform rating and $50 price target. The firm says the maker of ophthalmic and hospital-based injectable therapies is one of the fastest-growing companies in the specialty pharmaceuticals sector. William Blair thinks consolidation will likely continue within the specialty/generics market and feels Akorn represents an attractive asset. The stock closed yesterday up 38c to $39.75.